Immunome Reports First Quarter 2021 Financial Results
– IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing –
– IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies –
– Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer –
– Raised $27 million in gross proceeds in a private placement –